Search results for "LDL apheresis"

showing 5 items of 5 documents

Extracorporeal circuit heparinization in selective low density lipoprotein apheresis: changes in patient hemostasis and low molecular weight heparin …

1993

Treatment by low density lipoprotein (LDL) apheresis using dextran sulfate columns (DSC) leads to hemostasis alterations with prolonged activated partial thromboplastin time (APTT) of more than 120 seconds. In order to explain this hypocoagulability, we studied hemostasis parameters both in patients and in the extracorporeal circulation (ECC). Hemostasis changes are first related to unfractionated heparin (UFH)—needed to avoid circuit coagulation—which leads to high residual heparinemia in the patient (more than 3 times the recommended level for therapeutic use). Second, the hypocoagulability is induced by a coagulation factor decrease (primarily factors V, VIH, and X) mainly due to an adso…

Adultmedicine.medical_specialtyExtracorporeal Circulationmedicine.drug_classLow molecular weight heparinHyperlipoproteinemia Type IIInternal medicinemedicineHumansHemostasismedicine.diagnostic_testbusiness.industryExtracorporeal circulationAnticoagulantDextran SulfateNadroparinHematologyGeneral MedicineHeparinMiddle AgedBlood Coagulation FactorsSurgeryLipoproteins LDLApheresisLDL apheresisHemostasisCardiologyBlood Component RemovalbusinessPartial thromboplastin timemedicine.drugJournal of clinical apheresis
researchProduct

LDL apheresis in a homozygous familial hypercholesterolemic child aged 4.5.

1997

Preliminary experience with the efficacy and safety of dextran sulfate cellulose low-density lipoprotein (LDL) apheresis for the treatment of a 4.5-year-old girl with homozygous familial hypercholesterolemia and coronary artery disease is reported. The decrease of the most atherogenic apolipoprotein B-containing lipoproteins, low-density lipoprotein (LDL) and lipoprotein(a) (Lp [a]), were in the ranges of 63.1-68.7%, and 52.5-58.6%, respectively. The child tolerated LDL apheresis without any clinically significant complications. Therefore, she was submitted to a long-term program of treatment at intervals of 15 days. The experience suggests the possibility of an early beginning of extracorp…

Homozygous Familial Hypercholesterolemiamedicine.medical_specialtyApolipoprotein BBiomedical EngineeringMedicine (miscellaneous)BioengineeringCoronary Disease4.5 years-old girlFamilial hypercholesterolemiaBiomaterialsHyperlipoproteinemia Type IIchemistry.chemical_compoundInternal medicinemedicineCoronary Heart DiseaseHumansHyperlipoproteinemia Type IIbiologybusiness.industryCholesterolHomozygoteGeneral MedicineLipoprotein(a)Low Density Lipoprotein (LDL) apheresis; 4.5 years-old girl; Homozygous Familial Hypercholesterolemia; Coronary Heart Diseasemedicine.diseaseLipoproteins LDLApheresisEndocrinologyCholesterolLow Density Lipoprotein (LDL) apheresischemistryLDL apheresisChild Preschoolbiology.proteinBlood Component Removallipids (amino acids peptides and proteins)FemalebusinessLipoproteinLipoprotein(a)Artificial organs
researchProduct

Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis--comparison of performance charac…

2007

For many years dextran sulfate adsorption (DSA) treatment of separated plasma has been an established technology for low-density lipoprotein (LDL)-elimination. Recently a system for the treatment of whole blood based on DSA was introduced into clinical practice. To further characterize DSA treatment of whole blood, the performance characteristics of both DSA modalities were compared at two investigational sites with two alternative LDL apheresis systems being already in routine clinical use. In prospective cross-over design, DSA whole blood treatment was compared with a whole blood polyacrylate LDL adsorption system (DALI) in one study group. DSA for plasma treatment was compared with Lipid…

Malemedicine.medical_specialtymedicine.medical_treatmentUrologyAcrylic ResinsFibrinogenchemistry.chemical_compoundmedicineHumansWhole bloodbusiness.industryCholesterolDextran SulfateBlood Component RemovalFibrinogenHematologyGeneral MedicineCholesterol LDLHemoperfusionAtherosclerosisSurgerybody regionsApheresischemistryLDL apheresisBlood Component RemovalFemalebusinessFiltrationmedicine.drugLipoproteinJournal of clinical apheresis
researchProduct

Hipercolesterolemia familiar homocigota: adaptación a España del documento de posición del grupo de consenso sobre hipercolesterolemia familiar de la…

2015

Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening disease characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). The Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society (EAS) has recently published a clinical guide to diagnose and manage HoFH (Eur Heart J. 2014;35:2146-57). Both the Spanish Society of Atherosclerosis (SEA) and Familial Hypercholesterolaemia Foundation (FHF) consider this European Consensus document of great value and utility. However, there are particularities in our country which advise to ha…

medicine.medical_specialtyEzetimibeHomozygous familial hypercholesterolaemiaDiagnosisMedicinePharmacology (medical)Lipoprotein cholesterolNational healthEzetimibabusiness.industryAtherosclerotic cardiovascular diseaseDiagnósticoAféresisStatinsHipercolesterolemia familiar homocigotaLomitapidaEzetimibeLomitapidePatient managementLDL apheresisFamily medicineEuropean atherosclerosis societylipids (amino acids peptides and proteins)ApheresisCardiology and Cardiovascular MedicinebusinessEstatinasmedicine.drug
researchProduct

In vivo metabolism of LDL subfractions in patients with heterozygous FH on statin therapy

2004

LDL can be subfractionated into buoyant (1.020-1.029 g/ml(-1)), intermediate (1.030-1.040 g/ml(-1)), and dense (1.041-1.066 g/ml(-1)) LDLs. We studied the rebound of these LDL-subfractions after LDL apheresis in seven patients with heterozygous familial hypercholesterolemia (FH) regularly treated by apheresis (58 +/- 9 years, LDL-cholesterol = 342 +/- 87 mg/dl(-1), triglycerides = 109 +/- 39 mg/dl(-1)) and high-dose statins. Apolipoprotein B (apoB) concentrations were measured in LDL subfractions immediately after and on days 1, 2, 3, 5, and 7 after apheresis. Compartmental models were developed to test three hypotheses: 1) that dense LDLs are derived from the delipidation of buoyant and in…

medicine.medical_specialtyVery low-density lipoproteinApolipoprotein Blow density lipoprotein metabolismFamilial hypercholesterolemiaQD415-436Biochemistrychemistry.chemical_compoundEndocrinologyInternal medicinerebound kineticsmedicinesmall dense low density lipoproteinsdensity gradient ultracentrifugationbiologyfamilial hypercholesterolemiaChemistryCholesterollow density lipoprotein subtypesCell BiologyMetabolismmedicine.diseaseEndocrinologyApheresisLDL apheresisbiology.proteinDensity gradient ultracentrifugationlipids (amino acids peptides and proteins)Journal of Lipid Research
researchProduct